Clinical Trials | November 13, 2025
Philogen updates on Fibromun clinical study developments
FIBROSARC did not meet its primary PFS endpoint in the final analysi
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Subscribe To Our Newsletter & Stay Updated
